Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Summary

This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide as a single-agent treatment in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).

Timeline

Start

2017-08-20

Primary completion

2021-12-31

Completion

2021-12-31

Drugs

Indications